Katherine Pollard, PhD, director of the convergence science initiative at the Gladstone Institutes, has been selected as a Chan Zuckerberg Investigator.
News and Highlights
A trio of Gladstone scientists are studying the basic biology of the heart to guide the discovery of new therapies for conditions such as congenital heart disease and heart failure.
Gladstone scientists are mapping the connections and functions of brain cells to identify new drug targets to treat psychiatric disorders.
Anti-cancer drug prevented less weight gain and caused mice to burn more calories thanks to higher levels of metabolism-boosting brown fat.
Scientists discover an enzyme that that could be targeted to treat both Alzheimer’s disease and frontotemporal dementia.
New details learned about a key cellular protein could lead to treatments for neurodegenerative diseases, such as Parkinson’s, Huntington’s, Alzheimer’s, and amyotrophic lateral sclerosis (ALS).
Research on a gene mutation that causes holes in the hearts of infants revealed insights into how the heart develops and how it stays healthy.
A new biopharmaceutical company, Tenaya Therapeutics Inc., will build on discoveries in cardiovascular disease research made at the Gladstone Institutes, concentrating on regenerative medicine and drug discovery for heart failure.
The delayed antiviral immune response allows the virus to remain undetected in the vagina, which can increase the risk of fetal infection during pregnancy.
Gladstone scientists discover how to control the cacophony of electrical activity in the brain, stopping seizures and reducing deficits related to Alzheimer’s disease.